# Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/revolutionary-breakthrough-fda-approves-vyjuvek-the-first-topical-gene-therapy/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Afsheen Khan,Rumaisa Riaz,Saad Ashraf,Aymar Akilimali |
| Citations | 30 |
| DOI | 10.1097/ms9.0000000000001422 |
| Fields | Biochemistry, Genetics and Molecular Biology,Materials Science |
| Open Access | true |
| OA Status | gold |
| OA URL | https://doi.org/10.1097/ms9.0000000000001422 |
| OpenAlex ID | https://openalex.org/W4387701594 |
| PMID | 38098548 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Saad Ashraf](https://scholariq.org/researchers/saad-ashraf/)

## Paper journal

- [Annals of Medicine and Surgery](https://scholariq.org/journals/annals-of-medicine-and-surgery/)

## Paper primary topic

- [Skin and Cellular Biology Research](https://scholariq.org/topics/skin-and-cellular-biology-research/)

## Paper topics

- [Skin and Cellular Biology Research](https://scholariq.org/topics/skin-and-cellular-biology-research/)
- [Transgenic Plants and Applications](https://scholariq.org/topics/transgenic-plants-and-applications/)
- [Silk-based biomaterials and applications](https://scholariq.org/topics/silk-based-biomaterials-and-applications/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.